What is Q32 Bio Inc. Annual Net Profit?

Q32 Bio Inc. Annual Net Profit rose 11.18% in the last year to $47.73 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Q32 Bio Inc. Price to Earning Ratio?

Q32 Bio Inc. Price to Earning Ratio is -0.56, which is negative.

What is Q32 Bio Inc. Stock Price?

Q32 Bio Inc. Stock Price fell 86.95% and underperformed its sector by 96.85% in the past year.

What is Q32 Bio Inc. Quarterly Net profit?

Q32 Bio Inc. Quarterly Net profit rose 47.58% YoY to $14.19 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Q32 Bio Inc. Mutual Fund Holding?

Q32 Bio Inc. Mutual Fund Holding decreased by 7.36% in the last quarter to 12.55.

What is Q32 Bio Inc. Promoter Share Holding?

Q32 Bio Inc. Promoter Share Holding stayed the same in the most recent quarter at 0.16%.

What is Q32 Bio Inc. Institutional Holding?

Q32 Bio Inc. Institutional Holding increased by 8.65% in the last quarter to 70.28.

How is the Q32 Bio Inc. today?

The Q32 Bio Inc. today is trading in the green, up by 5.31% at 2.18.

How has Q32 Bio Inc. performed historically?

The Q32 Bio Inc. is currently trading up 5.31% on an intraday basis in the past week the index rose 9.00%. The index has been down -32.51% in the past quarter and fell -86.95% in the past year. You can view this in the overview section.

Q32 Bio Inc. XNAS: QTTB

Q32 Bio Inc. Live Share Price Today, Share Analysis and Chart

Name: Q32 Bio Inc.: Is Infosys Ltd. worth buying?
Item: Q32 Bio Inc.
Rating: 0.82066675
Author: Trendlyne DVM scores

Download real time

2.18 0.11 (5.31%)

95.95% Fall from 52W High

51,269 XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Q32 Bio Inc. is on 31 Mar 2025 for the purpose of Q32 Bio Inc Annual Report for 2024 See details

Q32 Bio Inc. Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	26.6
PE TTM Negative PE TTM Unavailable in chosen country	-0.6
Price to Book Below industry Median Unavailable in chosen country	1.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	70.3
Revenue Growth Qtr YoY % High in industry Unavailable in chosen country	100
Operating Revenue growth TTM % High in industry Unavailable in chosen country	100
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	47.6
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	11.2
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-39.8

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

9.2 / 100

Technically Bearish

23.7 / 100

1Yr Price target upside is 527%

3 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Q32 Bio Inc. Stock Price Analysis

Day Price Range 5.3% 1 Day return Unavailable in chosen country	2.2 (LTP) 22.2 LowHigh
Week Price Range 9.0% 1 Week return Unavailable in chosen country	2.2 (LTP) 22.3 LowHigh
Month Price Range -15.2% 1 Month return Unavailable in chosen country	2.2 (LTP) 1.82.7 LowHigh
52 Week Price Range -87.0% 1 Year return Unavailable in chosen country	2.2 (LTP) 1.853.8 LowHigh

View full Share Price History

Q32 Bio Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Q32 Bio Inc.'s Revenue was lower than average estimate 2 times in past 2 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-4.2

Avg. Estimate

-4.2

Low Estimate

-4.3

High Estimate

-3.9

Current EPS

Avg. Estimate

Consensus Recommendation

3 ANALYST Recommendations

BUY

The consensus recommendation from 3 analysts for Q32 Bio Inc. is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Q32 Bio Inc. Stock Analysis

Q32 Bio Inc. stock analysis with key metrics, changes, and trends.

Q32 Bio Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$47.73 M	11.18%	positive	Annual Net Profit rose 11.18% in the last year to $47.73 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-0.56	-	negative	Price to Earning Ratio is -0.56, which is negative.
Stock Price	$2.18	-86.95%	negative	Stock Price fell 86.95% and underperformed its sector by 96.85% in the past year.
Quarterly Net profit	$14.19 M	47.58%	positive	Quarterly Net profit rose 47.58% YoY to $14.19 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Mutual Fund Holding	12.55 %	-7.36%	negative	Mutual Fund Holding decreased by 7.36% in the last quarter to 12.55.
Promoter Share Holding	0.16 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 0.16%.
Institutional Holding	70.28 %	8.65%	positive	Institutional Holding increased by 8.65% in the last quarter to 70.28.

VIEW LESS

Loading data..

Q32 Bio Inc. - Company Profile

What does Q32 Bio Inc. do?

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Q32 Bio Inc. Management structure

All Gross Remunerations are in USD

Ms. Jodie P. Morrison

Chief Executive Officer and Director

2024

Gross Remuneration

Year

Mr. Lee Kalowski, M.B.A.

Chief Financial Officer, President and Principal Accounting Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Q32 Bio Inc. Live Share Price Today, Share Analysis and Chart

95.95% Fall from 52W High

Q32 Bio Inc. Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Q32 Bio Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Q32 Bio Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Q32 Bio Inc.'s Revenue was lower than average estimate 2 times in past 2 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 3 analysts for Q32 Bio Inc. is BUY

Q32 Bio Inc. Stock Analysis

Q32 Bio Inc. stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 11.18% in the last year to $47.73 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -0.56, which is negative.

Stock Price fell 86.95% and underperformed its sector by 96.85% in the past year.

Quarterly Net profit rose 47.58% YoY to $14.19 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Mutual Fund Holding decreased by 7.36% in the last quarter to 12.55.

Promoter Share Holding stayed the same in the most recent quarter at 0.16%.

Institutional Holding increased by 8.65% in the last quarter to 70.28.

Q32 Bio Inc. - Company Profile

What does Q32 Bio Inc. do?

Q32 Bio Inc. Management structure

Ms. Jodie P. Morrison

Chief Executive Officer and Director

Mr. Lee Kalowski, M.B.A.

Chief Financial Officer, President and Principal Accounting Officer

Q32 Bio Inc. Board of directors

Ms. Kathleen D. Laporte

Independent Director

Mr. Mark T. Iwicki

Chairman of the Board

Dr. Arthur O. Tzianabos, PhD

Director

Ms. Jodie P. Morrison

Chief Executive Officer and Director

Ms. Mary T. Thistle

Independent Director

Dr. David S. Grayzel, M.D.

Independent Director

Q32 Bio Inc. FAQ

How is Q32 Bio Inc. today?

Q32 Bio Inc. today is trading in the green, and is up by 5.31% at 2.18.

How has Q32 Bio Inc. performed historically?

Q32 Bio Inc. is currently trading up 5.31% on an intraday basis. In the past week the stock rose 9.00%. stock has been down -32.51% in the past quarter and fell -86.95% in the past year. You can view this in the overview section.